FDA
-
-
-
-
-
-
-
IMV Inc. to Present at Three Investor Conferences in September
-
-
-
-
-
-
-
IMV’s Lead Immunotherapy to be Investigated in Breast Cancer
-
-
-
-
-
-
-
IMV to Participate in Two Upcoming Investor Events
-
-
-
-
-
-
-
IMV's T (IMV) Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck’s Keytruda® in PD-L1 Positive Patients with r/r DLBCL
-
-
-
-
-
-
-
IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020
-
-
-
-
-
-
-
IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results
-
-
-
-
-
-
-
Clinical Translational Data Supporting DPX-Survivac Mechanism of Action to be Presented at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
-
322,240 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

